A new Dev Update has arrived, teasing long-awaited changes like a Replay System, another map, anti-smurfing measures and more. Let's explore a quick recap of what players can expect.

AbCellera’s poster presentation is available for download here. About AbCellera’s T-Cell Engager Platform CD3 T-cell engagers have the potential to be a cornerstone of cancer treatment.

A nasal spray, referred to as nasal anti-CD3, could be the first FDA-approved treatment for traumatic brain injury, or TBI, that can be easily administered with no serious side effects, the ...

Biotech Novartis gives up on anti-CD40 antibody to treat Sjögren's due to 'benefit/risk profile' By James Waldron Jan 31, 2025 5:13am Novartis Autoimmune Diseases pipeline ...

Research showed that healthy infants mount a robust IgG response to the same epitope. “Anti-flagellin reactivity has been discovered and used in the clinic for Crohn’s diagnosis for more than two ...

NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its ...

Epitope binning for multiple antibodies simultaneously using mammalian cell display and DNA sequencing. Communications Biology, 2024; 7 (1) DOI: 10.1038/s42003-024-06363-7 ...

More information: Sara C. Schulte et al, HOGVAX: Exploiting epitope overlaps to maximize population coverage in vaccine design with application to SARS-CoV-2, Cell Systems (2023).

Nasal anti-CD3 has been shown to treat animals with a progressive form of experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis, by inducing regulatory T cells that ...